Introduction
Traditionally, the major focus of obstetricians in genetic screening and diagnosis has been on chromosomal abnormalities. There have been many recent reviews on the new developments in screening and diagnosis of chromosomal abnormality, especially in the first trimester of pregnancy [1 ,2 ] . Therefore, this article will focus on screening and diagnosis of non-chromosomal genetic diseases.
In the past decade, major breakthroughs in molecular biological technologies have greatly enhanced understanding of the molecular basis of monogenic genetic diseases as well as many non-fatal or chronic diseases, which opens up the possibility of precise prenatal diagnosis of these conditions. At the same time, the elucidation of the genetic basis of many chronic diseases or multifactorial diseases has put obstetricians in an increasingly difficult position with regard to the ethics of prenatal screening and diagnosis of these conditions. The two objectives of this review are to report the latest developments in molecular genetics and related technologies, which make a significant contribution to prenatal genetic screening and diagnosis, and to discuss the implications of these developments on the daily clinical practice of obstetricians and fetal medicine specialists.
Recent advances in human genetics
The discovery of the double helix structure of DNA marked the beginning of the era of molecular biology [3] , and the invention of the polymerase chain reaction (PCR) was a major breakthrough that has radically changed molecular genetics. Numerous new molecular tests based on the principles of PCR have been developed, enabling the completion of the Human Genome Project. The latest Human Genome Project report showed that the near complete sequence contains 2.85 billion nucleotides interrupted by only 341 gaps, including about 1% of the euchromatic region, and that the human genome seems to encode only 20 000-25 000 protein-coding genes [4 ] . The development of microchip technology enables the study of thousands of genes in one experiment. Whole human genome microarray is already available, which enables easy comparison between a normal genome and the genome of patients affected by a particular disease. This technique is named array comparative genomic hybridization, and will certainly lead to the identification of the chromosomal basis of existing genetic conditions and new syndromes [5 ] . Not before long, the genetic basis of most monogenic diseases should be known, which will greatly enhance the molecular prenatal diagnosis of this group of diseases.
There is no doubt that the most reliable and precise method of diagnosis and screening of a mutation or deletion is by molecular tests. The issue of screening and diagnosis of a genetic disease is more complicated since most genetic diseases are due to more than one mutation. If the mutation is known in a family, the molecular diagnosis of that genetic disease within the family is straightforward. If the exact mutation is not known, one may use a panel of known mutations. These traditionally have to be tested individually which is labor intensive; this approach thus becomes impractical when there are a large number of known mutations, such as for cystic fibrosis which has more than 1000. This problem could be overcome by the new microarray technology in which all known mutations can be studied in one single experiment [6 ] . This approach does however still carry a small risk that a negative result could be due to an unknown mutation not included in the panel rather than the absence of the disease. This could again be overcome by sequencing of the gene of interest, a technique which is becoming more widely available.
Advances in molecular technology have also enabled the discovery and understanding of non-classical inheritance patterns, including imprinting, uniparental disomy such as the Prader-Willi syndrome and Angelman syndrome, and inheritance due to trinucleotide repeat expansions such as myotonic dystrophy. In addition to being highly sensitive and precise, molecular biological techniques are capable of being automated, which minimizes the possibility of human error and contamination, and enables high-throughput testing. The major obstacle at present in molecular genetic screening and diagnosis is the high cost. However, as for any technology, this is unlikely to be the case in the future. With the completion of the Human Genome Project, it was estimated that in the next one or two decades, it would be possible to screen 2000 individuals for about 400 000 genetic markers for less than US$10 000, and to sequence the entire genome of an individual for less than US$1000 [7 ] .
Genetic screening
Genetic screening is a systemic search in a population for persons having a particular genotype. The term usually is used to describe the genetic testing of people without a family history of the disease in question. There are two basic applications of general screening, outlined below.
The first application is the early detection of individuals affected by a serious genetic disease before the onset of symptoms. This early detection is usually only considered to be worthwhile if it is possible to alter the outcome by early identification and interventions. Most genetic screening tests for this purpose are implemented as neonatal screening programs. The best example is the neonatal screening of phenylketonuria, an autosomal recessive condition, which has been very successful in the prevention of severe mental retardation in thousands of children and adults [8] .
Population-wide neonatal screening is a major public health issue which is usually coordinated and implemented by the local health authorities, rather than determined by individual obstetricians. In the past, all genetic screenings have been, firstly, focused on monogenic conditions in which the genotypic and phenotypic correlations are strong and largely predictable; and, secondly, based on biochemical tests involving the protein product of the gene of interest. Recent advances in molecular biology enable highly accurate detection of genetic abnormalities and therefore provide the perfect tool for genetic screening, provided the genetic abnormality is known.
Most of the disorders in question are not, however, due to a single genetic abnormality. For example, there are over 300 known mutations responsible for phenylketonuria, over 1000 mutations for cystic fibrosis, and more than 200 mutations for beta-thalassemia. This means that the detection of all infants with a disorder would require testing not for a small number of mutations, but for many mutations, of which some may still be unknown. Testing for hundreds and thousands of mutations is possible with current technology, but would be enormously laborious and expensive. With further development, it will be possible to routinely sequence any gene of interest at low cost, and to predict the clinical effect of each mutation. Until then, neonatal genetic screening will probably continue to rely on biochemical analytical systems.
The second role of genetic screening is for heterozygotes; that is, the detection of carriers of recessive diseases. This has an important obstetric implication as appropriate counseling could be provided to couples when both are heterozygous. Traditionally, screening for carrier state is only possible if the carrier state is associated with identifiable clinical, hematological, biochemical or enzymatic abnormalities, such as the use of red cell mean corpuscular volume to screen for thalassemia, or hexosaminidase A to screen for Tay-Sachs disease. However, there is no simple test to detect carriers of many other autosomal recessive disorders such as cystic fibrosis. Modern molecular tests enable the accurate diagnosis of carriers in all situations provided the genetic mutation is known. The limitation of molecular screening is that it can only be used for known mutations. This method is therefore particularly useful among populations in which the disease of interest is caused by a limited number of known mutations. For example, three mutations accounted for 98.8% of all genetic abnormalities of Tay-Sachs disease among the Jewish Ashkenazi population [9] . Since the sensitivity of enzyme assay ranged only from 93.1% to 99.1%, DNA testing should be the preferred screening procedure, although it does not identify all mutations.
It is in the foreseeable future that gene-chip technology, which enables the study of thousands and tens of thousands of genetic mutations in one experiment, will be used for the screening of carriers. Technologies develop so fast that our problem will no longer be what we can test for, but rather what we should test for. The indiscriminate use of molecular testing would result in the identification of huge numbers of carriers, which would require confirmatory and family testing, as well as genetic counseling. This could prove to be an immense burden on the time available to the limited number of genetic counselors, and might lead to unnecessary long-term psychological effects [10 ] .
With the improved understanding of the genetic basis of many multigenic and multifactorial disorders, chronic diseases, cancers, and response to medicinal drugs, there is increasing debate on and demand for genetic screening for these conditions. Common arguments for genetic screening include: knowledge of the gene variants has the potential to allow 'personalized' drug therapy and to avoid therapeutic failure and serious side effects [11 ] ; awareness of the presence of a cancer-related gene could allow the use of prophylactic treatment to prevent the occurrence of cancer, such as prophylactic mastectomy in BRCA mutation carriers [12 ] ; and knowing of a genetic predisposition to a chronic disease may allow behavioral modification to minimize the chance of developing the disease, or even gene therapy to prevent its occurrence [13 ] . There are still many unknowns and much uncertainty in this area, and therefore any argument for genetic screening requires further and better scientific evidence.
New approaches in prenatal diagnosis
Here, the discussion will focus only on preimplantation and non-invasive prenatal diagnosis.
Preimplantation genetic diagnosis
Preimplantation genetic diagnosis (PGD) is used for the evaluation of embryos resulting from artificial reproductive technologies to ensure that only normal embryos are replaced into the uterine cavity. The most commonly used technique is blastomere biopsy, in which one or two cells from an 8-10-cell embryo are removed for genetic study. In addition to the exclusion of aneuploidies, PGD has been successfully used in a number of monogenic diseases [14 ] , as well as for social sexing [15] . Although this technology has been reported on for more than a decade, its development was hampered by the technical difficulty of having only one or two cells to work with. Although there are numerous assisted reproductive technology (ART) centers, only a minority are able to offer PGD. Recent developments in molecular testing technology such as minisequencing will certainly further enhance the diagnostic possibilities of PGD; however, it is unlikely that there will be any significant increase in the number of centers that are able to provide it. Unlike at other molecular biological laboratories, which can even accept samples shipped from overseas, at the ART center PGD must be performed on site because of the limited time available for embryo transfer after the biopsy of polar bodies or embryos. Therefore, the impact of this technology on prenatal screening and diagnosis in the foreseeable future is likely to be limited.
Celocentesis
The extra-celomic cavity is the most prominent structure during early pregnancy. With advancing gestation, the amniotic cavity expands with a concomitant reduction in the size of the extra-celomic cavity. The amnion eventually fuses with the chorion, obliterating the extracelomic cavity by 12-14 weeks of gestation. Celocentesis is an invasive procedure, which provides fetal cells and genetic material for possible early prenatal diagnosis.
In 1993 Jurkovic et al. [16] reported a 96% success rate in retrieving celomic fluid by between 6 and 10 weeks of gestation, but cytogenetic analysis always failed. Cruger et al. [17] alone have reported successful cell culture and cytogenetic analysis of cells from nine out of 10 celomic fluid samples. Most studies have focused on the usefulness of celocentesis in prenatal diagnosis by molecular testing, including for fetal sex determination [18] , betathalassemia [19] , sickle cell disease, Marfan syndrome and paternity testing [20 ] . In a non-randomized comparative study, the procedure-related fetal loss associated with celocentesis was estimated to be approximately 2% up to 1 week after the procedure [21] .
With more sophisticated molecular tests, it is likely that prenatal diagnosis of a wide spectrum of diseases using a celomic fluid sample will be proven to be feasible. This procedure enables very early prenatal diagnosis which even chorionic villus sampling cannot provide. In the near future, celocentesis will not play a major role in prenatal diagnosis at least until the safety of this procedure and its diagnostic accuracy are better defined. However, it is likely that this procedure will become a viable alternative to other existing tests if very early prenatal diagnosis is required.
Fetal cells and nucleic acid in maternal circulation
Non-invasive prenatal diagnosis has been a long-sought goal. There are numerous reports confirming the presence of fetal cells in the maternal circulation during pregnancy, at a very low concentration of about 1-6 fetal cells per ml of maternal blood [22, 23] . The key to success for any attempt at reliable prenatal diagnosis is the effective isolation, purification and identification of these few fetal cells from the background maternal blood cells. Unfortunately, all blood processing protocols for the isolation of fetal cells developed so far are labor-intensive and costly, with sensitivity and specificity levels that are unacceptable for routine prenatal diagnostic purposes. Although occasional successful molecular diagnoses have been reported, the largest collaborative study in this field, of 2774 participants, showed that at least one fetal cell could only be detected in 41.4% of samples from women carrying a non-trisomy 21 fetus, with a false positive rate of 0.6% [24] . It is unlikely that there will be any major breakthrough in this area in the next few decades; this approach of non-invasive prenatal diagnosis has in fact been described as a 'dead duck', at least with the current technology [25] .
On the other hand, the recent discovery of the existence of cell-free fetal DNA in the maternal circulation has the potential to revolutionize prenatal diagnosis. The presence of cell-free fetal DNA in the maternal circulation was first reported only 7 years ago in 1997 by Lo et al. [26] , who used the detection of Y-chromosomal DNA sequences derived from a male fetus by the conventional PCR method as a model system. The presence of Y-chromosomal DNA sequences in the maternal circulation is unequivocal evidence of the presence of a male fetus. Using a real-time PCR system, fetal DNA has been found to constitute 3.4% of all cell-free DNA in maternal plasma during the late first to mid-second trimester, and this percentage rises with advancing gestation [27] . Numerous studies have now confirmed the reliable detection of cell-free fetal DNA from maternal plasma as early as 5 weeks of gestation [28 ] . Cell-free fetal DNA is quickly eliminated from the maternal circulation after delivery with a mean half-life of 16.3 min [29] . The fact that, unlike fetal cells, cell-free DNA does not persist in the maternal circulation after delivery is important from the point of view of prenatal diagnosis.
Although it has only been 7 years since its discovery, cellfree DNA has already been successfully used for the noninvasive prenatal diagnosis of many diseases. In a study of 131 pregnant women with a fetus at risk of a wide range of X-linked genetic diseases, fetal gender was correctly predicted by fetal DNA from maternal plasma samples taken between 10 and 13 weeks of gestation, with 100% concordance [30] . The ability to accurately detect fetally derived Y-chromosomal sequences in maternal plasma in early pregnancy can be applied in the prenatal diagnosis of sex-linked disorders to avoid invasive tests for those carrying a female fetus, or in cases where fetal sex affects clinical management such as in the use of corticosteroid therapy for congenital adrenal hyperplasia in those carrying female but not male fetuses [31 ] .
Likewise, in principle, the analysis of fetal DNA in maternal plasma could be used reliably for the noninvasive prenatal diagnosis of any paternally inherited autosomal dominant diseases or traits, provided the molecular abnormality is known. The detection of the diseasecausing allele in the maternal plasma would confirm an affected fetus. Successful examples include single-gene disorders [32] , trinucleotide repeat diseases [33] , fetal aneuploidy [34] and fetal rhesus genotyping.
Rhesus iso-immunization is of obstetrical importance only if the pregnant woman is rhesus negative while her husband is rhesus positive. Although not an X-linked disease, a similar approach could be used for fetal rhesus genotyping from plasma samples of a D-negative pregnant woman; namely the detection of fetally derived RHD sequence in the plasma of a rhesus D-negative pregnant woman (who does not have the RHD gene) indicates the presence of a rhesus D-positive fetus. Noninvasive prenatal fetal rhesus genotyping was first reported in 1998 [35] , and has been confirmed by many other studies to be highly reliable, especially from the second trimester of pregnancy onward. Since 2001, The International Blood Group Reference Laboratory in Bristol (UK), which provides a fetal blood group genotyping service to obstetricians caring for immunized pregnant women with heterozygous partners, started offering fetal D typing using cell-free fetal DNA in maternal plasma. This has significantly reduced the number of invasive procedures carried out in the UK for fetal D grouping [36 ] , and is the most cost-effective approach to restricting the use of anti-D prophylaxis in pregnancies involving a D-positive fetus [37 ] .
A similar approach could be used in the prenatal assessment of autosomal recessive disorders. If a paternally derived mutant allele could be identified in maternal plasma, the fetus would have a 50% chance of inheriting the disease and therefore an invasive diagnostic test is indicated. On the other hand, the absence of such a paternally derived mutant allele, or the demonstration of a paternal marker which is linked to the normal paternal allele, indicates the fetus would be at most a carrier (if the baby inherits a mutant allele from the mother) and therefore an invasive test is not indicated. Successful application has been reported for congenital adrenal hyperplasia and beta-thalassemia [38, 39, 40 ] .
At present, a definitive prenatal diagnosis of autosomal recessive conditions by fetal DNA analysis in maternal plasma is generally considered impossible. Since fetal DNA in maternal plasma is mixed with a large amount of maternal DNA, the maternal mutant allele will always be present in maternal plasma, and therefore its analysis would not be useful to differentiate the fetal status of inheritance. However, recent studies have showed that there are physical and functional differences between fetal DNA and maternal DNA. Fetal DNA is smaller in size [41 ] and has a different methylation status [42] . Further research may reveal additional differences between fetal and maternal DNA, which may eventually enable differentiation between the two and therefore the prenatal diagnosis of autosomal recessive disorders noninvasively.
New challenges for the obstetrician and fetal medicine specialists
At present, molecular genetic diagnosis is possible for more than 900 diseases. This list is expected to increase dramatically with the advances in related molecular technology. However, such a development poses new problems for practicing obstetricians.
Quality assurance
Although molecular tests are considered to be highly sensitive and accurate, this is only so if the technology is applied correctly. For example, different blood processing protocols have been shown to have significant effects on the concentration of fetal DNA in maternal plasma [43] . Both pre-analytical and analytical proficiency might affect the reliability of any genetic test result, and therefore both internal and external quality controls are important. The consequence of poor quality assurance could be devastating, resulting in the termination of a normal pregnancy, the missed diagnosis and birth of an abnormal baby, or even the conviction of an innocent in a criminal investigation [44 ] . Unfortunately, the diagnostic accuracies of most genetic laboratories are not known to the end user.
A review conducted by 28 experts, representatives of professional organizations, industries, and federal agencies, has identified the major problems of quality assurance in human molecular genetic testing [45 ] . The major factor inhibiting development of comprehensive performance evaluation, proficiency testing and quality assurance programs is the lack of positive control samples (i.e. samples containing well-defined mutations associated with a disease of public health importance). The lack of standardized testing methods between laboratories, due to the rapid development in molecular analytical systems, further hampers the development of universally accepted external quality assurance programs. Also, the panel recognized that the use of an overall generic or method-based approach to quality assurance or control would be inadequate to cover all aspects of genetic testing because of numerous test-specific and diseasespecific issues. This remains a major problem to be solved in the coming decade.
Ethical, legal and social issues
It is increasingly likely that a large number of genetically determined conditions, traits, and genetic markers of adult-onset conditions could be screened for and diagnosed either prenatally or after birth. The knowledge of a certain genetic predisposition might be of clinical relevance. For example, those with hereditary hemochromatosis could be advised to avoid iron supplementation, and women who carry mutations in BRCA2 will benefit more by taking tamoxifen. At present, however, the application of genetic testing to most of these conditions is severely hampered for a number of reasons; in particular, that there are insufficient prospective data to establish allelespecific disease risk, and even fewer from the modeling of gene-gene or gene-environment interactions [44 ] . However, new information emerges everyday, and new novel preventive measures to minimize the risk associated with a particular genotype are continually being reported. When these technologies are commercially available, should they be offered to pregnant women, in the form of either prenatal diagnosis or neonatal screening? Should they be discussed with the woman involved to seek her wishes, or only if she requests this? Or should they not be offered even if requested? This is an extremely controversial issue, with major social and ethical implications. The issue that raises most ethical concern is the potential abuse of prenatal screening, and subsequent termination of pregnancies for conditions that develop only in a subset of those who carry particular genes [46 ] , the presence of a particular trait, or even hair color or the shape of the lips! Obstetricians will certainly be among the first health-care professionals needing to face this difficult dilemma.
Although the use of prenatal genetic diagnosis to ensure the birth of a baby without a disability is controversial enough, the wish of some couples to use similar technology in order to have a baby with a specific disability, such as a deaf couple wishing to screen for and make an active choice to have a deaf child, is even more so [47 ]. This is a new problem that we may have to face with the arrival of new technology. Furthermore, information generated from a genetic screening test may have an impact with regard to marital relationships, employment, and insurance. Many patients consider that obtaining genetic information important to their health care is not worth the risk of discrimination stemming from the use of such information by potential insurers or employers [48 ] .
Consent and medico-legal concern
Even for a specific condition, such as trisomy 21, it is already difficult enough for different people to agree on what constitutes appropriate and adequate counseling, such as what information patients should be given, how and when the information should be presented, and who should present the information. Because it is likely that tests will be developed to screen for thousands of genetic conditions at one go, it will not be possible to provide meaningful counseling about each and every one of the tests. Accordingly, Elias and Annas [49] as early as 1994 argued that there will be a need to develop a 'generic consent for genetic screening' to provide sufficient information to permit individuals to give informed consent to screening, but not so much information as to amount to misinformation that would serve only to make the process misleading or meaningless. This is a highly simplified view of a very complex issue, and it is hard to believe that a 'generic consent' would provide enough information for a couple to decide which specific screening test they should or should not have.
Conclusion
The rapid development in molecular biological technique enables not only the elucidation of the molecular basis of various genetic and multifactorial diseases, but also their rapid and accurate diagnosis. In the next decade, it is likely that there will be an exponential increase in the number of diseases and mutations that can be detected or diagnosed during pregnancy, not only using samples obtained by invasive tests such as amniocentesis and chorionic villus sampling, but also noninvasively by examining the cell-free DNA in the maternal plasma. The arrival of the molecular genetic era also leads to many new ethical, social and medico-legal problems and dilemmas that obstetricians will have to face in the near future. There is an urgent need for the development of a new model for provision of genetic screening and diagnosis. 
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